Turning One Drug for One Patient Into a Shared Platform: U.S. Invests $27.7 Million to Tackle Rare Childhood Immune Disorders

The challenge of rare genetic diseases is often not that the disease-causing gene is unknown, but that each mutation affects too few patients to support a development process that starts over from drug design and manufacturing through clinical trials. The U.S. Advanced Research Projects Agency for Health (ARPA-H) is now providing up to $27.7 million to support the AEGIS program, led by the Innovative Genomics Institute (IGI) at the University of California, Berkeley, in an effort to turn “making one drug for one patient” into a reusable platform.

AEGIS targets approximately 500 congenital immune deficiencies. These diseases arise from abnormalities in genes related to the immune system, and severe cases can cause fatal infections in early childhood. Some patients may receive hematopoietic stem cell transplants or existing gene therapies, but the procedures, hospitalization requirements, and costs are all substantial. The program’s central concept is to deliver editing tools directly into the bone marrow to correct hematopoietic stem cells, eliminating steps such as removing cells, modifying them outside the body, chemotherapy preconditioning, and reinfusion.

Technically, the team will develop base editing and prime editing in parallel to cover different types of disease-causing variants, while also developing lipid nanoparticles capable of directing editing tools to the bone marrow. IGI says the relevant delivery methods have demonstrated efficiency in mice and nonhuman primates. However, the safety and efficacy of bone marrow-targeted in vivo gene editing have not yet been established in these children, and editing efficiency, unintended modifications, immune responses, and long-term effects will all be critical hurdles for clinical translation.

What will truly determine whether the platform can scale is not only the editors themselves. ARPA-H requires THRIVE program teams to demonstrate in the first year that the same platform can produce multiple drugs with shared biodistribution and toxicology profiles; advance a first-in-human umbrella trial capable of accommodating different products and disease phenotypes in the third year; and expand the umbrella trial investigational new drug application in the fifth year. AEGIS will also incorporate rapid, noninvasive methods of identifying patients, with the aim of shortening the time from diagnosis to treatment.

The IGI team’s five-year goal is to treat 10 children, reduce the development time for personalized editors to under three months, and lower the cost to below $200,000. These figures remain engineering and execution targets, and funding will be disbursed according to the achievement of accelerated milestones. Whether different patients can share manufacturing, quality-control, and safety data will also still require regulatory approval. The team has pledged to publicly release nonclinical data, regulatory correspondence, and trial results, which may help other rare-disease programs assess whether this model can be replicated.

Background

The creation of a personalized in vivo gene-editing therapy for an infant with CPS1 deficiency in approximately six months has demonstrated that ultra-rare mutations can reach clinical use within an extremely short period. AEGIS’s next step is to transform that highly customized, resource-intensive single case into an institutionalized process that can continuously serve multiple immune disorders. If the platform succeeds, the breakthrough will not be limited to a particular CRISPR tool, but will address the longstanding economic and regulatory dilemma in rare-disease drug development: the fewer the patients, the harder it is to develop a treatment.